{
    "xml": "<topic id=\"PHP5274\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/melphalan\" basename=\"melphalan\" title=\"MELPHALAN\">\n<title>MELPHALAN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_503\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/alkylating-drugs/melphalan\">Melphalan</xref>\n</p>\n<data name=\"vtmid\">544002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_348581499\" title=\"Alkylating agents\">Alkylating agents</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP70763\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/melphalan\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Multiple myeloma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;micrograms/kg daily for 4 days, dose to be repeated every 6 weeks, dose may vary according to regimen.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Polycythaemia vera</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 6&#8211;10&#8239;mg daily for 5-7 days, then reduced to 2&#8211;4&#8239;mg daily until satisfactory response, then reduced to 2&#8211;6&#8239;mg once weekly.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By regional arterial perfusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70853\" outputclass=\"importantSafetyInformation\" rev=\"1.9\" parent=\"/drugs/melphalan\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70890\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/melphalan\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP70749\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/melphalan\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (melphalan).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70674\" outputclass=\"sideEffects\" rev=\"1.30\" parent=\"/drugs/melphalan\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Interstitial pneumonitis</ph>; <ph outputclass=\"sideEffect\">life threatening pulmonary fibrosis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression (delayed)</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">male sterility</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">premature menopause</ph>; <ph outputclass=\"sideEffect\">secondary malignancy</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">extravasation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Secondary malignancy</p>\n<p>Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70878\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/melphalan\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs. </p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises adequate contraception during treatment in men or women.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70736\" outputclass=\"pregnancy\" parent=\"/drugs/melphalan\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70911\" outputclass=\"breastFeeding\" parent=\"/drugs/melphalan\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70699\" outputclass=\"renalImpairment\" parent=\"/drugs/melphalan\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose initially (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70649\" outputclass=\"monitoringRequirements\" parent=\"/drugs/melphalan\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor full blood count before and throughout treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5274-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/melphalan\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76342\" title=\"Tablet\" namespace=\"/drugs/melphalan/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76334\" title=\"Powder and solvent for solution for injection\" namespace=\"/drugs/melphalan/powder-and-solvent-for-solution-for-injection\">Powder and solvent for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"4\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_503\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/alkylating-drugs/melphalan\" title=\"Melphalan\" count=\"1\" rel=\"link\">Melphalan</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76342\" namespace=\"/drugs/melphalan/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76334\" namespace=\"/drugs/melphalan/powder-and-solvent-for-solution-for-injection\" title=\"Powder and solvent for solution for injection\" count=\"1\" rel=\"link\">Powder and solvent for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5274",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/melphalan",
    "basename": "melphalan",
    "title": "MELPHALAN",
    "interactants": [
        {
            "id": "bnf_int_503",
            "label": "Melphalan"
        }
    ],
    "vtmid": "544002",
    "drugClassification": [
        "Alkylating agents"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Multiple myeloma",
                        "html": "Multiple myeloma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "150 micrograms/kg daily for 4 days, dose to be repeated every 6 weeks, dose may vary according to regimen.",
                        "html": "<p>150&#8239;micrograms/kg daily for 4 days, dose to be repeated every 6 weeks, dose may vary according to regimen.</p>"
                    },
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Polycythaemia vera",
                        "html": "Polycythaemia vera"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 6&#8211;10 mg daily for 5-7 days, then reduced to 2&#8211;4 mg daily until satisfactory response, then reduced to 2&#8211;6 mg once weekly.",
                        "html": "<p>Initially 6&#8211;10&#8239;mg daily for 5-7 days, then reduced to 2&#8211;4&#8239;mg daily until satisfactory response, then reduced to 2&#8211;6&#8239;mg once weekly.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities",
                        "html": "Localised malignant melanoma of the extremities and localised soft tissue sarcoma of the extremities"
                    }
                ],
                "specificity": {
                    "routes": [
                        "regional arterial perfusion"
                    ],
                    "textContent": "By regional arterial perfusion",
                    "html": "By regional arterial perfusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (melphalan).",
                "html": "<p>Appendix 1 (melphalan).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Interstitial pneumonitis",
                        "html": "Interstitial pneumonitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "life threatening pulmonary fibrosis",
                        "html": "life threatening pulmonary fibrosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression (delayed)",
                        "html": "bone-marrow suppression (delayed)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "male sterility",
                        "html": "male sterility",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "premature menopause",
                        "html": "premature menopause",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "secondary malignancy",
                        "html": "secondary malignancy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Secondary malignancy",
                "textContent": "Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.",
                "html": "<p>Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises adequate contraception during treatment in men or women.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs. </p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturer advises adequate contraception during treatment in men or women.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose initially (consult product literature).",
                "html": "<p>Reduce dose initially (consult product literature).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count before and throughout treatment.",
                "html": "<p>Monitor full blood count before and throughout treatment.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76342",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76334",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_503",
                "label": "Melphalan",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76342",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76334",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}